High concentrations of MDMA ('ecstasy') and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells

Neuropharmacology

Volumn 61, Issue 1-2, 2011, Pages 202-208

  Hondebrink, Laura ^a,b   Meulenbelt, Jan ^a,b,c   Meijer, Marieke ^a   Van Den Berg, Martin ^a   Westerink, Remco H S ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

3,4 methylenedioxyamphetamine; 3,4 methylenedioxymethamphetamine; Amperometry; Ca 2+ homeostasis; Catecholamine exocytosis; Drugs of abuse

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CALCIUM ION; DOPAMINE; DOPAMINE TRANSPORTER; FURA 2;

AMPEROMETRY; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL MEMBRANE DEPOLARIZATION; CELL VACUOLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG MECHANISM; DRUG POTENCY; EVOKED RESPONSE; EXOCYTOSIS; EXTRACELLULAR SPACE; INTRACELLULAR TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REACTION TIME; REGULATORY MECHANISM;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; CALCIUM; CELL SURVIVAL; DOPAMINE; EXOCYTOSIS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PC12 CELLS; RATS; SYNAPTIC VESICLES;

EID: 79957832473     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.03.028     Document Type: Article

References (54)

1. Adell, A., Artigas, F., 2004. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci. Biobehav. Rev. 28, 415-431.
2. Chen, T.K., Luo, G., Ewing, A.G., 1994. Amperometric monitoring of stimulated catecholamine release from rat pheochromocytoma (PC12) cells at the zeptomole level. Anal. Chem. 66, 3031-3035.
3. Chu, T., Kumagai, Y., DiStefano, E.W., Cho, A.K., 1996. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem. Pharmacol. 51, 789-796.
4. Cole, J.C., Sumnall, H.R., 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine(MDMA).Neurosci. Biobehav. Rev. 27,199-217.
5. Colliver, T.L., Hess, E.J., Pothos, E.N., Sulzer, D., Ewing, A.G., 2000. Quantitative and statistical analysis of the shape of amperometric spikes recorded from two populations of cells. J. Neurochem. 74, 1086-1097. (Pubitemid 30104305)
6. Crawford, C.A., Williams, M.T., Kohutek, J.L., Choi, F.Y., Yoshida, S.T., McDougall, S.A., Vorhees, C.V., 2006. Neonatal 3,4- methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [35S] GTPgammaS binding in adult rats. Brain Res. 1077, 178-186.
7. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br. J. Pharmacol. 121, 1735-1743.
8. David, H.N., Ansseau, M., Abraini, J.H., 2005. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res. Brain Res. Rev. 50, 336-360.
9. DAWN, 2010. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2007. National Estimates of Drug-Related Emergency Department Visits, Rockville, MD.
10. 2+ und pH, Ionenmessungen in Zellen und Geweben. Spektrum Akademischer Verleger, Heidelberg.
11. de la Torre, R., Farre, M., Ortuno, J., Mas, M., Brenneisen, R., Roset, P.N., Segura, J., Cami, J., 2000. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol. 49, 104-109.
12. Dingemans, M.M., Ramakers, G.M., Gardoni, F., van Kleef, R.G., Bergman, A., Di Luca, M., van den Berg, M., Westerink, R.H., Vijverberg, H.P., 2007. Neonatal exposure to brominated flame retardant BDE-47 reduces long-term potentiation and postsynaptic protein levels in mouse hippocampus. Environ. Health Perspect. 115, 865-870.
13. EMCDDA, 2007. The State of the Drugs Problem in Europe. Annual report 2007. European Monitoring Centre for Drugs and Drug Addiction.
14. Escobedo, I., O'Shea, E., Orio, L., Sanchez, V., Segura, M., de la Torre, R., Farre, M., Green, A.R., Colado, M.I., 2005. A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br. J. Pharmacol. 144, 231-241.
15. Esteban, B., O'Shea, E., Camarero, J., Sanchez, V., Green, A.R., Colado, M.I., 2001. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl) 154, 251-260.
16. Fitzgerald, J.L., Reid, J.J., 1993. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch. Pharmacol. 347, 313-323.
17. Green, A.R., Mechan, A.O., Elliott, J.M., O'Shea, E., Colado, M.I., 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55, 463-508. (Pubitemid 37013213)
18. Greene, L.A., Tischler, A.S., 1976. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA 73, 2424-2428.
19. Gudelsky, G.A., Yamamoto, B.K., Nash, J.F., 1994. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur. J. Pharmacol. 264, 325-330.
20. Han, D.D., Gu, H.H., 2006. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 6, 6.
21. Hiramatsu, M., Cho, A.K., 1990. Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29, 269-275. (Pubitemid 20096391)
22. Hondebrink, L., Meulenbelt, J., Timmerman, J.G., van den Berg, M., Westerink, R.H., 2009. Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure. J. Neurochem. 111, 624-633.
23. Iravani, M.M., Asari, D., Patel, J., Wieczorek, W.J., Kruk, Z.L., 2000. Direct effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse 36, 275-285. (Pubitemid 30257312)
24. Johnson, M.P., Hoffman, A.J., Nichols, D.E., 1986. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132, 269-276.
25. Kalant, H., 2001. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165, 917-928.
26. Kanthasamy, A., Sprague, J.E., Shotwell, J.R., Nichols, D.E., 2002. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 114, 917-924.
27. Kolbrich, E.A., Goodwin, R.S., Gorelick, D.A., Hayes, R.J., Stein, E.A., Huestis, M.A., 2008. Plasma pharmacokinetics of 3,4- methylenedioxymethamphetamine after controlled oral administration to young adults. Ther. Drug Monit. 30, 320-332.
28. Lin, P.L., Tsai, M.C., Lu, G.L., Lu, D.Y., Chuang, C.M., Yang, H.Y., Huang, S.S., Chen, Y.H., 2010. Ecstasy and methamphetamine elicit action potential bursts via different mechanisms in a central snail neuron. Neurotoxicology 31, 26-41.
29. McCann, U.D., Szabo, Z., Seckin, E., Rosenblatt, P., Mathews, W.B., Ravert, H.T., Dannals, R.F., Ricaurte, G.A., 2005. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30, 1741-1750. (Pubitemid 43086031)
30. Moyano, S., Frechilla, D., Del Rio, J., 2004. NMDA receptor subunit and CaMKII changes in rat hippocampus induced by acute MDMA treatment: a mechanism for learning impairment. Psychopharmacology (Berl) 173, 337-345. (Pubitemid 38703807)
31. Mueller, M., Yuan, J., Felim, A., Neudorffer, A., Peters, F.T., Maurer, H.H., McCann, U.D., Largeron, M., Ricaurte, G.A., 2009. Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab. Dispos. 37, 2079-2086.
32. Nair, S.G., Gudelsky, G.A., 2004. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat. Brain Res. 1013, 168-173. (Pubitemid 38757422)
33. Nash, J.F.,1990. Ketanserin pretreatment attenuatesMDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 47, 2401-2408.
34. Nash, J.F., Brodkin, J., 1991. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 259, 820-825.
35. Partilla, J.S., Dempsey, A.G., Nagpal, A.S., Blough, B.E., Baumann, M.H., Rothman, R.B., 2006. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther. 319, 237-246.
36. Pifl, C., Nagy, G., Berenyi, S., Kattinger, A., Reither, H., Antus, S., 2005. Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters. J. Pharmacol. Exp. Ther. 314, 346-354.
37. Romero, C.A., Bustamante, D.A., Zapata-Torres, G., Goiny, M., Cassels, B., Herrera-Marschitz, M., 2006. Neurochemical and behavioural characterisation of alkoxyamphetamine derivatives in rats. Neurotox. Res. 10, 11-22.
38. Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I., Partilla, J.S., 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41.
39. Rothman, R.B., Dersch, C.M., Ananthan, S., Partilla, J.S., 2009. Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release. J. Pharmacol. Exp. Ther. 329, 718-728.
40. Rudnick, G., Wall, S.C., 1992. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. U S A 89, 1817-1821.
41. Samyn, N., De Boeck, G., Wood, M., Lamers, C.T., De Waard, D., Brookhuis, K.A., Verstraete, A.G., Riedel, W.J., 2002. Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci. Int. 128, 90-97.
42. Schmidt, C.J., Levin, J.A., Lovenberg, W., 1987. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol. 36, 747-755.
43. Schmidt, C.J., Sullivan, C.K., Fadayel, G.M., 1994. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62, 1382-1389.
44. 2+/ calmodulin kinase II inhibitor KN-62. J. Cell Sci. 108 (Pt 7), 2619-2628.
45. 2+ channels. Eur. J. Pharmacol. 366, 281-292.
46. Shankaran, M., Gudelsky, G.A., 1998. Effect of 3,4- methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol. Biochem. Behav. 61, 361-366.
47. Sulzer, D., Rayport, S., 1990. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5, 797-808.
48. Sulzer, D., Sonders, M.S., Poulsen, N.W., Galli, A., 2005. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406-433.
49. Westerink, R.H., de Groot, A., Vijverberg, H.P., 2000. Heterogeneity of catecholamine-containing vesicles in PC12 cells. Biochem. Biophys. Res. Commun. 270, 625-630.
50. 2+. J. Neurochem. 80, 861-873.
51. 2+-induced vesicular catecholamine release from rat PC12 cells. Brain Res. 957, 25-36.
52. Westerink, R.H., 2006. Targeting exocytosis: ins and outs of the modulation of quantal dopamine release. CNS Neurol. Disord. Drug Targets 5, 57-77.
53. Westerink, R.H., Ewing, A.G., 2008. The PC12 cell as model for neurosecretion. Acta Physiol. (Oxf) 192, 273-285.
54. Wilson, M.A., Ricaurte, G.A., Molliver, M.E., 1989. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 28, 121-137. (Pubitemid 19026748)